Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Hodgkin Disease 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Primary Myelofibrosis 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1B-cell Malignancies 1B-Cell Malignancies 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 7Whole-Body Irradiation 7Cyclophosphamide 7fludarabine 6Mycophenolic Acid 6Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Sirolimus 2Cyclosporine 2Antilymphocyte Serum 2Allopurinol 2venetoclax 1itacitinib 1carmustine, poliferprosan 20 drug combination 1Melphalan 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Cytarabine 1Cyclosporins 1Carmustine 1Association 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × itacitinib × Lymphoid × Clear all
NCT05823571 2025-09-18

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡